Abstract
Introduction Bedaquiline (BDQ) is a lifesaving new tuberculosis (TB) drug undergoing global scale-up. Data on resistance emergence in programmatic settings, especially in patients resistant to other drugs with potentially weak background regimens, is scarce. Such individuals are a priority for novel drug access yet a potential source of population-level resistance.
Methods We collected culture isolates from 40 drug resistant (DR)-TB patients, culture-positive after ≥4 months of BDQ-based treatment at baseline (pre-BDQ treatment initiation) and follow-up (closest post-four-month isolate). We did MGIT960 (1μg/ml) BDQ drug susceptibility testing (DST), targeted deep sequencing (TDS; Rv0678, atpE, pepQ), and whole genome sequencing (WGS). Contemporaneous programmatic BDQ DST was unavailable.
Results Eight percent (3/40) of patients’ strains were BDQ resistant at baseline, and 47% (19/40) gained BDQ phenotypic resistance [88% (15/17) due to acquisition, 12% (2/17) reinfection]. Several single nucleotide polymorphisms and indels in rv0678 and pepQ were associated with phenotypic resistance but none in rv0676c and rv1979c (potential lineage markers). TDS detected low-level variants undetected by WGS, however, none were in genes without WGS-detected variants. Patients with baseline fluoroquinolone-resistance, clofazimine exposure, and ≤4 effective drugs were more likely to be BDQ-resistant at follow-up.
Conclusion BDQ resistance acquisition, for which we identified risk factors, was common in these programmatically treated patients. Our study highlights risks associated with implementing new drugs in such populations. Likely BDQ resistance transmission occurred. Routine BDQ DST should urgently accompany scale-up of new all oral regimens, however, rapid BDQ genotypic DST remains challenging given the diversity of variants observed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Doris Duke Charitable Foundation (Metcalfe), the U.S. National Institute of Allergy and Infectious Diseases (NIAID) (R01AI131939, Metcalfe and Engelthaler), the South African Medical Research Council (SAMRC), National Research Foundation (NRF), the Research Foundation Flanders (FWO Odysseus, G0F8316N, Van Rie), the Stellenbosch University Faculty of Medicine Health Sciences, a Swiss-South Africa Joint Research Award (Reference: 107799, South African National Research Foundation and the Swiss National Science Foundation, Cox and Gagneux), and a Wellcome Trust Fellowship (Cox: 099818/Z/12/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Stellenbosch University Health Research Ethics Committee (N09/11/296; N16/04/045), Western Cape Health Research Committee (WC_2016RP18_637), University of California San Francisco Human Research Protection Program (14-15090) and the University of Cape Town Human Research Ethics Committee (416/2014).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first author
Funding: This work was supported by the Doris Duke Charitable Foundation (Metcalfe), the U.S. National Institute of Allergy and Infectious Diseases (NIAID) (R01AI131939, Metcalfe and Engelthaler), the South African Medical Research Council (SAMRC), National Research Foundation (NRF), the Research Foundation Flanders (FWO Odysseus, G0F8316N, Van Rie), the Stellenbosch University Faculty of Medicine Health Sciences, a Swiss-South Africa Joint Research Award (Reference: 107799, South African National Research Foundation and the Swiss National Science Foundation, Cox and Gagneux), and a Wellcome Trust Fellowship (Cox: 099818/Z/12/Z).
Data Availability
All data produced in the present study are available upon reasonable request to the authors
